Juniper Pharmaceuticals, Inc.

juniper pharmaceuticals (nasdaq: jnp) is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health. juniper has a commercial product, crinone® 8% (progesterone gel), which is marketed by allergan, inc. in the u.s. and by merck kgaa, darmstadt, germany, in over 90 countries worldwide. juniper is accelerating development of its proprietary product pipeline, leveraging in-house formulation, pharmaceutical development, and manufacturing. r&d is substantially funded by cash flow generated by the crinone franchise and the contract pharmaceutical services provided by juniper pharma services. in q2 2015, the company initiated a phase ii study of col-1077, a 10% lidocaine bioadhesive gel intended as an acute use anesthetic for minimally invasive gynecologic procedures. enrollment is underway. future pipeline products will utilize juniper’s novel drug delivery technologies, including its proprietary bioadhesive delivery system